Fairmount Funds Management’s Crescent Biopharma CBIO Stock Holding History
Bought
Maintained
Sold
Other funds holding CBIO
OM
Fairmount Funds Management's CBIO Position: Q3 2026 in Review
Fairmount Funds Management increased its Crescent Biopharma (CBIO) stake by 31% in Q3 2026, buying an estimated $14.3M and bringing the position to 3,601,316 shares worth $52.5M. The position accounts for 3.3% of the portfolio, ranked #10.
Fairmount Funds Management first reported a position in CBIO in Q2 2025 and has held it in 6 quarters since. 106 funds tracked by Wall St. Rank hold CBIO as of Q3 2026.
- Fairmount Funds Management held 3,601,316 shares of Crescent Biopharma worth $52.5M as of Q3 2026.
- Fairmount Funds Management bought 853,450 Crescent Biopharma shares in Q3 2026, an estimated $14.3M.
- Crescent Biopharma made up 3.3% of Fairmount Funds Management's portfolio in Q3 2026, its #10 holding.
- Fairmount Funds Management first reported a position in Crescent Biopharma in Q2 2025 and has held it in 6 quarters since.
- 106 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2026.
Based on Fairmount Funds Management's 13F filing for Q3 2026, filed 16 Nov 2026.